An international consortium reported engineering bacterial pathways to overcome a decades‑old production bottleneck for doxorubicin, a core anthracycline chemotherapy. The work, published in Nature Communications, identified and corrected molecular inefficiencies in the biosynthetic route, enabling substantially increased yields of the complex natural product. The team combined genetic, enzymatic and fermentation engineering to restore and optimize key tailoring steps that previously limited scale‑up. One paper described the discovery of rate‑limiting enzymes; a companion report detailed strain engineering that lifts production ceilings. For oncology supply chains and small‑molecule natural product drugmakers, the advance could lower manufacturing costs and expand access to an essential cytotoxic used worldwide.